# Cardiac Safe Transplants for Systemic Sclerosis

> **NCT03593902** · PHASE2,PHASE3 · TERMINATED · sponsor: **Northwestern University** · enrollment: 9 (actual)

## Conditions studied

- Systemic Sclerosis
- Scleroderma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** rATG
- **DRUG:** Methylprednisolone
- **DRUG:** G-CSF
- **BIOLOGICAL:** IVIg
- **BIOLOGICAL:** Autologous Stem Cells

## Key facts

- **NCT ID:** NCT03593902
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-17
- **Primary completion:** 2019-10-03
- **Final completion:** 2019-10-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** PI Sabbatical
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593902, "Cardiac Safe Transplants for Systemic Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03593902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*